{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:05:27Z","timestamp":1791201927892,"version":"4.2.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ad.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T10:52:18Z","timestamp":1688813538000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain"],"prefix":"10.1016","volume":"115","author":[{"given":"E.","family":"Daud\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Bordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zulaica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.07.001_bib0155","first-page":"e1","article-title":"La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en Espa\u00f1a","volume":"93","author":"Puig","year":"2019","journal-title":"Revista Espa\u00f1ola de Salud P\u00fablica"},{"key":"10.1016\/j.ad.2023.07.001_bib0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjd.16332","article-title":"A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey","volume":"179","author":"Griffiths","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0165","first-page":"167","article-title":"A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values","volume":"6","author":"M\u00f8ller","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.ad.2023.07.001_bib0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.07.001_bib0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ad.2013.02.009","article-title":"Cumulative life course impairment: the imprint of psoriasis on the patient's life","volume":"105","author":"Ros","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.07.001_bib0180","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","article-title":"Risankizumab: a review in moderate to severe plaque psoriasis","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2023.07.001_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Daud\u00e9n","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.001_bib0190","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.07.001_bib0195","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0200","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.001_bib0205","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.001_bib0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2023.07.001_bib0215","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/s10198-014-0600-x","article-title":"Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary","volume":"15","author":"Her\u00e9di","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ad.2023.07.001_bib0220","unstructured":"Fundaci\u00f3n Piel Sana-Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (AEDV). BIOBADADERM. Registro Espa\u00f1ol de acontecimientos adversos de terapias sist\u00e9micas en psoriasis; 2020. https:\/\/biobadaderm.fundacionpielsana.es\/post.aspx?id=236&title=Informe-Biobadaderm-2020."},{"key":"10.1016\/j.ad.2023.07.001_bib0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ad.2010.10.016","article-title":"BIOBADADERM, The Spanish Registry of adverse events associated with biologic drugs in dermatology: first report","volume":"102","author":"Rivera","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.07.001_bib0230","first-page":"692","article-title":"Adaptaci\u00f3n transcultural al espa\u00f1ol del cuestionario Dermatology Life Quality Index (DLQI): el \u00edndice de calidad de vida en dermatolog\u00eda","volume":"89","author":"de Tiedra","year":"1998","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2023.07.001_bib0235","unstructured":"Reilly associates. WPAI:PSO (v2.0 Spanish-Spain). http:\/\/www.reillyassociates.net\/WPAI_Translations.html."},{"key":"10.1016\/j.ad.2023.07.001_bib0240","first-page":"93","article-title":"Predictors of biologic treatment of psoriasis: a non-interventional study","volume":"6","author":"Puig","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ad.2023.07.001_bib0245","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/jdv.14195","article-title":"A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain","volume":"31","author":"Puig","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.001_bib0250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1346-8138.12465","article-title":"Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study)","volume":"41","author":"Sanchez-Carazo","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0255","first-page":"577","article-title":"The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review","volume":"107","author":"Burgos-Pol","year":"2016","journal-title":"Actas Dermo-Sifiliogr (Engl Ed)"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2023.07.001_bib0260","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2023.07.001_bib0265","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0270","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.07.001_bib0275","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/13696998.2021.1937187","article-title":"Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data","volume":"24","author":"Bagel","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.ad.2023.07.001_bib0280","first-page":"583","article-title":"Economic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis","volume":"23","author":"Feldman","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ad.2023.07.001_bib0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0290","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s13555-021-00564-2","article-title":"Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab","volume":"11","author":"Houghton","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2023.07.001_bib0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.07.001_bib0300","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ad.2020.01.001","article-title":"Opinion survey on persistence of biologic therapies in patients with moderate to severe psoriasis","volume":"111","author":"Puig","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023005306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023005306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:16:28Z","timestamp":1757553388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023005306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001731023005306"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.07.001","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}